

DAFTAR PUSTAKA

- Ahmad AI, 2011. 'Glycated Hemoglobin: Past, Present and Future are We ready for the Change', *J Pak Med Assoc*, Vol 61 (4) : 383-8
- American Diabetes Association, 2015. 'Standard of Medical Care in Diabetes', *Diabetes Care*, 38 (Suppl. 1):S4
- Aronson D, Rayfield EJ, 2002. 'How Hyperglycemic Promote Atherosclerosis: Molecular Mechanism', *Pubmed Central* p: 1-2
- Bandeira SM, Fonseca LJS, Guedes GS, Rabelo LA, Goulart MOF, Vasconcelos SML. 2013, 'Oxidative Stress as an Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus'. *Int. J. Mol. Sci.* 14(2), 3265-84
- Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al., 2012. 'Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guidelines', *J Clin Endocrinol Metab*, Vol 97, p:2969-89
- Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan V, 2012. 'HbA1c: Predictor of Dyslipidemia and Atherogenicity in Diabetes Mellitus', *IJBMS*, Vol. 2, No. 1, p:25-7
- Casella S, Bielli A, Mauriello A and Orlandi A, 2015. 'Molecular Pathways Regulating Macrovascular Pathology and Vascular Smooth Muscle Cells Phenotype in Type 2 Diabetes'. *Int. J. Mol. Sci.* 16, p:24353-68;
- Chang JB, Chu NF, Syu JT, Hsieh AT, Hung YR, 2011. 'Advanced Glycation End Products (AGEs) in Relation to Atherosclerotic Lipid Profiles in Middle-Aged and Elderly Diabetic Patients', *Lipids in Health and Disease*, 10:228
- Chen L, Magliano DJ, Zimmet PZ, 2012, 'The Worldwide Epidemiology of Type 2 Diabetes Mellitus-Present and Future Perspectives', *Nat. Rev. Endocrinol*, Volume 8, p: 228–36
- Codario RA, 2005.'Type 2 Diabetes, Prediabetes and The Metabolic Syndrome' in: *The Primary Care Guide to Diagnosis and Management*, Human Press, pp:1-9
- Dahlan S, 2004. 'Statistika Untuk Kedokteran dan Kesehatan', editor Susalit E, Wngge G, Setiawan H, Arkans, Jakarta.
- Dabiasova M, 2006. 'AIP-Atherogenic Index of Plasma as A significant predictor of Cardiovascular Risk', in *Research to Practice*, vol 1 p:64-71
- Franssen R, Monajemi H, Stoes ESG and Kastelein JJP, 2011, 'Obesity and dyslipidemia', *Med Clin N Am* , vol. 95 , p: 893–902.

- Ginsberg HN, Li Zhang Y and Ono AH, 2005, 'Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes', *Diabetic MC Today*, p: 20-26.
- Golberg IJ, 2001. 'Diabetic Dyslipidemia: Causes and Consequences', *JCE&M*, Vol 86(3): 965-72
- Goldin A, Beckman J, Schmidt AM, Creager MA, 2006. 'Advanced Glycation End-Products Sparking development of Diabetic Vascular Injury', *Circulation*, Vol 114, p: 597-605
- Gugliucci A, 2015. 'The Mailard Reactin and Diabetes Mellitus' in: *Diabetes and Diabetic Complication*, University of Warwick, p: 1-34
- Hadi HAR and Suwaidi JA, 2007.'Endothelial Dysfunction in Diabetes', *Vascular Health and Risk Management* 3(6) p:853-76
- Hepher PR, Kahn HB, 1999. Glucose Transporters and Insulin Action. *The New Englan Journal of Medicine*,Vol. 341, No. 4, p: 248-57
- Hilbert H, Lifshitz MS, 2007. 'Lipids and Dyslipidemia', in *Henry's Clinical Diagnosis and Management by Laboratory Methods*, 21st ed, McPherson RA and Pincus MR, Elsevier Inc.Philadelphia, p:200-10
- Hilawe EH, Yatsuya H, Kawaguchi L, Aoyama A, 2013. 'Differences By Sex In The Prevalence Of Diabetes Mellitus, Impaired Fasting Glycaemia And Impaired Glucose Tolerance In Sub-Saharan Africa: A Systematic Review And Meta-Analysis *Bulletin of the World Health Organization*', Vol 91 p:671-82D.
- Jakuš V, Rietbrock N, 2004. 'Advanced Glycation End-Products and The Progress of Diabetic Vascular Complications', *Physiol. Res.* 53, p:131-42
- Jelantik IGMG, Haryanti E, 2014.'Hubungan faktor Risiko Umur, Jenis kelamin, Kegemukan dan Hipertensi dengan kejadian Diabetes Melitus', in *Media Bina Ilmiah*, p:39-43
- Jones A and Persaud S, 2010. Islet Function and Secretion', in *Textbook of Diabetes*, 4th Edition, ed. Holt R, Cockram A, Flyvbjerg A and Goldstin B, Sussex: Blackwell, p: 104-25.
- Kaku K, 2010. 'Pathophysiology of Type 2 Diabetes and Its Treatment Policy', *JMAJ* ,Vol. 53, No. 1.
- Kariadi S, 2005. 'Resistensi Insulin dan Disfungsi Sel Beta Pankreas Sebagai Dasar Pemilihan Obat pada Diabetes Melitus tipe 2'. *Forum Diabetes Nasional III*, p: 112-22.
- Kohli P and Cannon CP, 2012. 'Tryglyceride: How Much Credit do They Deserve?', *Med Clin N Am*, Vol. 96, p:39-55

- Laakso M, 2010. 'Cardiovascular Disease in Type 2 Diabetes From population to Man Mechanisms', *Diabetes Care*, Volume 33, No.2, p:442-49
- Libby P and Plutzky J, 2002. 'Diabetic Macrovascular, the Glucose Paradox?'. *Circulation*, Vol 106: 2760-3
- Mazzone T, Chait A, Plutzky J, 2008. 'Cardiovascular disease Risk in Type 2 Diabetes Mellitus: Insights from Mechanistic Studies', *Lancet* 371, p: 1800-09
- Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN et al., 2011. 'Triglyceride and Cardiovascular Disease A Scientific Statement from the American Heart Association', *Circulation*, vol 123, p: 2292-333
- Momin AA, Bankar MP, Bhoite GM, 2013. Glycosilated Hemoglobin (HbA1c): Association with Dyslipidemia and Predictor of Cardiovascular Disease in Type 2 Diabetes Mellitus Patients', in *International Journal of Health Sciences and Research*, Vol 3 (8), p:40-5
- Otto-Buczowska E and Jarosz-Chobot P, 2001, 'Lipid metabolism. I. Role of insulin in lipid metabolism', *Pol Merkur Lekarski.*, vol. 10, no. 57, p: 180-4.
- Perkeni, 2011, 'Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia', PB Perkeni, Jakarta.
- Powers AC, 2005, 'Diabetes Mellitus' in *Harrison's Principles of Internal Medicine*, 16th eds, New York, McGraw-Hill Companies, Inc, p: 2152-6
- Priyadi R, Saraswati MR, 2012. 'Hubungan Antara Kendali Glikemik dan Profil Lipid Pada penderita Diabetes Melitus Tipe 2', *FK Udayana*, p:1-12
- Radoi V, Lixandru D, Mohora M, Virgolici, 2012. 'Advanced Glycation End Products in Diabetes Mellitus: Mechanism of Action and Focused Treatment', *Proc. Rom. Acad., Series B*, p: 9-19
- Ryden L, Standl E, Bartnik M, Berghe G, Betteridge J, Boer M et al., 2007. 'Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Disease', *Europ.Heart J Supplement* 9 (Supplement C), C3-C74
- Sasisekhar TVD, Shabana S, 2013. 'Can HbA1c Act as Surrogate Marker for Cardiovascular Risk?', *JDMS*, Vol. 3, Issue 4, p: 39-43
- Schalkwijk CG, Ligtoet N, Twaalhoven H, Jager A, Blaugers HGT, Schlikgemann RO et al., 1999. 'Amadori Albumin in Type 1 Diabetic Patient: Correlation with Marker of Endothelial Function, Association with Nephropaty and Localization in Retinal Capillaries', *Diabetes*, Vol 48, p:2446-52
- Scheen AJ, 2003, 'Pathophysiology of Type 2 Diabetes', *Acta Clinica Belgica*, Volume 58 No. 6. p: 335-41

- Shiraki T, Miura Y, Sawada T, Okada T, Sakuraota Y, Muto T et al., 2011. 'Glycated Albumin Suppressed Glucose Induce Insulin Secretion by Impairing Glucose Metabolism in Rat Pancreatic B-Cell', *Nutrition and Metabolism*, Vol 8, p: 1-10
- Silbernagl S dan Lang F, 2000, *Color Atlas of Pathophysiology*, Thieme Stuttgart, New York. p:286-8
- Smith CM, Marks AD and Lieberman MA, 2005, *Marks' basic medical biochemistry: a clinical approach*, Philadelphia: Lippincott Williams & Wilkins.
- Stirban A and Tschöpe D, 2015. 'Vascular Effects of Dietary Advanced Glycation End Products', Hindawi Publishing Corporation, *International Journal of Endocrinology*, Volume 2015
- Tiwari BK, Pandey KB, Abidi AB, Rizvi SI, 2013, 'Marker of Oxidative Stress during Diabetes Mellitus', Hindawi Pub.Corp. *Journal of Biomarkers*, Vol 2013.
- Ullah A, Khan A, Khan I, 2015. 'Diabetes Mellitus and Oxidative Stress – A Concise Review', *Saudi Pharmaceutical Journal*.
- Ulrich P, Cerami A, 2001. 'Protein Glycation, Diabetes and Aging', *The Endocrine Journal*, Vol 56, p: 1-22
- Uttra KM, Devrajani BR, Shah SZA, Devrajani T, Das T, Raza S et al., 2011. "Lipid Profile of Patients with Diabetes mellitus", *World Appl. Sci. J.*, 12 (9), p: 1382-4
- Valliyot B, Sreedharan J, Muttappallymyalil J, Valliyot SB. 2013, 'Risk Factors of Type 2 Diabetes Mellitus in the Rural Population of North Kerala', India: A Case Control Study. *Diabetologia Croatica* 42-1.
- van de Woestijne AP, Monajemi H, Kalkhoven E and Visseren FLJ, 2011, 'Etiology and pathophysiology adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management', *Obes Rev*, vol. 12, p: 829–840.
- Vasdev S, Gill VD, Singal PK, 2006. 'Modulation of Oxidative Stress Induced Change in Hypertension and Atherosclerosis by Antioxidants', *Exp Clin Cardiol*, Vol 11, p:206-17
- Yamagishi SI and Imaizumi T, 2005. 'Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potensial Therapeutic Strategy', *Curren Pharmaceutical Design*, Vol 11, p:2279-99
- Yamagishy SI, Matsui T, 2010. 'Advanced Glycation End-products, Oxidative Stress and Diabetic Nephropathy' in: *Oxidative Medicine and Cellular Longevity*, p:101-8

Yamagishi SI, Nakamura N, Suematsu M, Kaseda K, and Matsui T. 2015, 'Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes', *Mol.Med* 21 (supplement 1), S32-40

Yu R, Hui H, Melmed S, 2005. 'Insulin Secretion And Action' in : *Endocrinology Basic And Clinical Principles* 2nd Edition, Humana Press Inc. New Jersey, p: 311-20

Yuan G, Al-Shali KZ and Hegele RA, 2007, 'Hypertriglyceridemia: Its Etiology, Effects and Treatment', *CMAJ*, vol. 176, no. 8, p. 1113-20.

